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ABSTRACT
Ubiquitination (also known as ubiquitylation) is a post-translational
modification that creates versatility in cell signalling and regulates a
multitude of cellular processes. Its versatility lies in the capacity to
form eight different inter-ubiquitin linkages through the seven lysine
residues of ubiquitin and through its N-terminal methionine (M1). The
latter, referred to as linear or M1 linkage, is created by the linear
ubiquitin chain assembly complex (LUBAC), the only E3 ligase known
to date that is capable of forming linear ubiquitin chains de novo.
Linear ubiquitin chains are crucial modulators of innate and adaptive
immune responses, and act by regulating inflammatory and cell death
signalling. In this Cell Science at a Glance article and the
accompanying poster, we review the current knowledge on the role
of LUBAC and linear ubiquitination in immune signalling and human
physiology. We specifically focus on the role for LUBAC in signalling
that is induced by the cytokine tumour necrosis factor (TNF) and its
role in inflammation, gene activation and cell death. Furthermore, we
highlight the roles of deubiquitinases (DUBs) that cleave M1 linkages
and add an additional layer in the control of LUBAC-mediated immune
signalling.
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Introduction
Post-translational modifications of proteins enable and regulate
cellular processes and physiological responses in a rapid and
versatile manner. Ubiquitination is one of the most common post-
translational modifications. It is both inducible and reversible and is
involved in controlling and fine-tuning countless signalling
cascades (Komander and Rape, 2012). Ubiquitination is
characterised by covalent attachment of ubiquitin to a target
protein. Attachment of a single ubiquitin to a substrate is called
monoubiquitination. Polyubiquitin chains are the result of an
elongation process in which substrate-attached ubiquitin itself
serves as the substrate. Two ubiquitin proteins can be conjugated
through the C-terminus of the incoming ubiquitin and one of the
seven lysine residues (K6, K11, K29, K33, K48 and K63) or,
alternatively, the N-terminal methionine residue (M1) of the
‘substrate’ ubiquitin (Komander and Rape, 2012). Here, we focus
on M1-linked ubiquitination, also called linear ubiquitination, and
the linear ubiquitin chain assembly complex (LUBAC), the only
known E3 ubiquitin-ligating enzyme producing M1 ubiquitin
linkages de novo. LUBAC and linear ubiquitination were first
described to be relevant in tumour necrosis factor (TNF) signalling
(Haas et al., 2009; Tokunaga et al., 2009). We will explain the
contribution of LUBAC to the formation of the TNF receptor 1
(TNFR1, also known as TNFRSF1A) signalling complex
(TNFR1-SC) and how it affects the outcome of TNFR1
stimulation functionally. Proper de-ubiquitination is as important
as ubiquitination itself for a physiologically balanced outcome.
The three DUBs that play a role in TNF signalling are OTU
deubiquitinase with linear linkage specificity (OTULIN),
cylindromatosis (CYLD) and A20 (also known as TNFAIP3),
and we will discuss their individual roles with respect to LUBAC
and linear ubiquitination. In addition, dysregulation of M1
ubiquitination is linked to a number of severe pathologies, and
we will highlight the importance of proper control of linear
ubiquitination in this context.
Composition and protein domains of LUBAC
LUBAC was first described in 2006 (Kirisako et al., 2006).
It consists of three subunits: HOIL-1-interacting protein (HOIP,
also known as RNF31), heme-oxidized iron-responsive element-
binding protein 2 ubiquitin ligase-1 (HOIL-1, also known
as RBCK1), and SH3 and multiple ankyrin repeat domains
protein (SHANK)-associated RBCK1 homology (RH)-domain-
interacting protein (SHARPIN) (Gerlach et al., 2011; Ikeda et al.,
2011; Tokunaga et al., 2011). All three LUBAC components
form a high-molecular-mass complex of presently unknown
stoichiometry with HOIP being the only catalytically active
subunit (Kirisako et al., 2006; Tokunaga et al., 2009). Proteins
in the LUBAC complex harbour numerous domains, which
are required for (1) formation of the complex, (2) its activity,
(3) regulation of LUBAC and (4) interaction with other proteins
(see poster).
Formation of the complex
The ubiquitin-like (UBL) domains of SHARPIN and HOIL-1 have
both been shown to bind to HOIP, the central component of
LUBAC. The interaction of the HOIL-1 UBL domain with the
ubiquitin-associated (UBA) domain of HOIP is well described
(Yagi et al., 2012), but the binding partner of the UBL domain of
SHARPIN in HOIP is still unclear: the UBA, as well as the second
nuclear protein localisation 4 (Npl4)-zinc-finger (NZF2) domain
in HOIP have been suggested to bind to the UBL domain of
SHARPIN (Gerlach et al., 2011; Ikeda et al., 2011; Tokunaga
et al., 2011).
Activity of LUBAC
The catalytic activity of LUBAC is provided by the RING-in
between RING–RING (RBR) domain in the C-terminus of HOIP
plus an extension that is referred to as the linear ubiquitin chain-
determining domain (LDD) (Gerlach et al., 2011; Kirisako et al.,
2006; Smit et al., 2012; Stieglitz et al., 2012, 2013; Tokunaga et al.,
2011). Interestingly, HOIL-1 also has an RBR domain; it is,
however, dispensable for the generation of linear ubiquitin chains
by LUBAC (Kirisako et al., 2006).
Regulation of LUBAC
The PNGase/UBA or UBX (PUB) domain in HOIP associates with
two different proteins: OTULIN and spermatogenesis-associated
protein 2 (SPATA2) (Draber et al., 2015; Elliott et al., 2016, 2014;
Kupka et al., 2016a; Rivkin et al., 2013; Schaeffer et al., 2014;
Schlicher et al., 2016; Takiuchi et al., 2014; Wagner et al., 2016).
Both proteins compete for binding to the PUB domain of HOIP and
are important regulators of LUBAC activity.
All three LUBAC components also contain ubiquitin-binding
domains (UBDs).
Interaction of LUBAC with other proteins
The NZF1 domain of HOIP, as well as the respective NZF domains
of HOIL-1 and SHARPIN show ubiquitin-binding capacity of
varying specificity (Haas et al., 2009; Ikeda et al., 2011; Sato et al.,
2011). The contribution of these different UBDs to the stability,
localisation and/or regulation of LUBAC as a consequence of its
binding to different types of polyubiquitin chains is still unclear.
Linear versus lysine-linked ubiquitination
The process of ubiquitination is a multi-stage catalytic cascade,
which requires the concerted action of three different classes of
enzymes (Pickart and Eddins, 2004). The process is initiated by
the ubiquitin-activating enzyme, also known as E1. This ATP-
dependent step is followed by the second step, which includes the
transfer of the now activated ubiquitin from E1 to the second
ubiquitin-conjugating enzyme (E2). The final step of the
ubiquitination cascade requires a ubiquitin-ligating enzyme (E3),
which catalyses the covalent attachment of the ubiquitin to its
substrate. This usually forms an isopeptide bond between the ε-
amino group of a lysine residuewithin the substrate and the carboxyl
group of the C-terminus of ubiquitin (Hershko and Ciechanover,
1998) (see poster). Often, monoubiquitination of a substrate is
followed by ubiquitin chain elongation (Komander and Rape, 2012).
Elongation through M1 ubiquitin linkages is unique in that true
peptide bonds are formed, as opposed to isopeptide bonds, which are
typical for all other inter-ubiquitin linkages (Kirisako et al., 2006;
Rieser et al., 2013). These bonds result from conjugation of the
C-terminal carboxyl group of the incoming ubiquitin with the
α-amino group of the N-terminal methionine (M1) of the substrate-
attached ubiquitin, rather than with an ε-amino group of one of its
lysine residues (Kirisako et al., 2006) (see poster). Initially, HOIP
was thought to recognise target proteins directly and to catalyse their
monoubiquitination and the subsequent elongation (Fujita et al.,
2014; Smit et al., 2013; Tokunaga et al., 2009). Recently, an
alternative model was proposed in which target proteins are first
modified with K63-linked ubiquitin chains that are subsequently
extended through M1 linkages by LUBAC, thereby generating
mixed inter-ubiquitin linked chains (Emmerich et al., 2013).
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The role of LUBAC in TNF signalling
TNF is a proinflammatory cytokine and a major regulator of
immune cells (Brenner et al., 2015). Binding of TNF to its receptor
TNFR1 results in the formation of a multiprotein complex across the
cell membrane, which activates a number of signalling cascades that
together trigger inflammation (Kupka et al., 2016b). LUBAC is
crucial for proper TNF signalling and its recruitment to the TNFR1-
SC results in M1 ubiquitination of different components of this
protein complex (Shimizu et al., 2015). This enables, on the one
hand, triggering of gene activation through nuclear factor κ-light-
chain-enhancer of activated B cells (NF-κB) and mitogen-activated
protein kinases (MAPKs) leading to upregulation of a plethora of
pro-survival and inflammatory genes, and, on the other hand,
prevention of cell death (Emmerich et al., 2013; Gerlach et al., 2011;
Haas et al., 2009; Ikeda et al., 2011; Kirisako et al., 2006; Tokunaga
et al., 2009) (see poster). Formation of the TNFR1-SC, also known
as complex I, is initiated by binding of TNF to TNFR1. This leads to
receptor trimerisation and recruitment of the protein TNFR1-
associated death domain (TRADD) and the receptor-interacting
serine/threonine-protein kinase 1 (RIPK1) to the intracellular death
domain of the receptors (Hsu et al., 1996, 1995). TNFR1-bound
TRADD serves as the adaptor for recruitment of TNF receptor-
associated factor 2 (TRAF2), which in turn brings two E3 enzymes –
the cellular inhibitor of apoptosis proteins 1 and 2 (cIAP1/2, also
known as DIAP1 and DIAP2, respectively) – to the complex (Rothe
et al., 1995; Shu et al., 1996). Recruitment to the TNFR1-SC activates
cIAPs, which attach K63-, K11- and K48-linked ubiquitin chains to
several components of the complex (Dynek et al., 2010; Gyrd-
Hansen and Meier, 2010), thereby enabling LUBAC recruitment to
complex I (Haas et al., 2009). TNFR1-recruited LUBAC linearly
ubiquitinates several complex components includingNF-κB essential
modulator NEMO (also known as IKKγ, encoded by IKBKG),
RIPK1, TRADD and TNFR1 (Draber et al., 2015; Gerlach et al.,
2011; Haas et al., 2009). Acting in concert, the cIAP1/2- and the
LUBAC-generated ubiquitin chains enable TNF-induced gene
activation (Dynek et al., 2010; Haas et al., 2009; Tokunaga et al.,
2009). The functional unit TAK1–TAB protein complex is recruited
through this ubiquitination cascade; it consists of transforming
growth factor-β-activated kinase 1 (TAK1, also known asMAP3K7),
TAK1-binding protein 1 (TAB1) and either of the ubiquitin-binding
proteins TAB2 or TAB3, which enable recruitment of this tripartite
complex to K63-linked ubiquitin chains (Ea et al., 2006; Kanayama
et al., 2004; Wang et al., 2001). Another functional unit that is
recruited through ubiquitin chains is the IκB kinase (IKK) complex,
which comprises the two inhibitor of κB kinases α and β (IKKα and
IKKβ, or IKK1 and IKK2; encoded by CHUK and IKBKB,
respectively) and NEMO (Zhang et al., 2000). Although it is able
to interact with K63- and K11-linked ubiquitin chains, the affinity of
NEMO for M1-linked chains is ∼100-fold higher. It is this high
affinity of NEMO towards M1 linkages that makes LUBAC such an
important factor for proper gene induction (Dynek et al., 2010;
Hadian et al., 2011; Laplantine et al., 2009; Rahighi et al., 2009; Wu
et al., 2006). Within the TNFR1-SC, the TAK1–TAB complex
activates MAPK cascades, which trigger the activation of the JUNN-
terminal kinase (JNK) and p38 pathways and result in activation of
the transcription factor AP-1 (Song et al., 1997;Winston et al., 1997),
whereas recruitment of the IKK complex to the TNFR1-SC activates
IKK1/2, resulting in NF-κB activation (Chen et al., 1996; Devin
et al., 2000).
Normally, TNF stimulation results in gene activation and not cell
death (Vandenabeele et al., 2010). Under certain circumstances,
however, a second TNF-induced signalling complex forms, referred
to as complex II, and this complex promotes cell death induction.
This can be caused by, among other reasons, cIAP inhibition or
LUBAC ablation (Fotin-Mleczek et al., 2002; Gerlach et al., 2011;
Peltzer et al., 2018, 2014; Vince et al., 2008). Complex II is
cytosolic and forms upon release of RIPK1 from complex I
(Micheau and Tschopp, 2003). A prerequisite for complex II
formation is thought to be the RIPK1 deubiquitination by CYLD
(O’Donnell et al., 2007, 2011; Wang et al., 2008). Whereas the
mechanism of complex-I-to-complex-II transition remains largely
unresolved, RIPK1 is known to be part of both complexes and to be
an important player in the induction of cell death. Recent
publications have shown that the phosphorylation of RIPK1 in
complex I on specific sites within the protein serves as a checkpoint
to prevent its activation through auto-phosphorylation, which is a
prerequisite for the transition to complex II, thereby keeping the
TNF signalling output pro-survival (Annibaldi and Meier, 2018).
Several kinases, including the p38 MAPK pathway targets MAPK-
activated protein kinase 2 (MK2, also known as MAPKAPK2) and
TAK1, the canonical kinases IKKα and IKKβ, as well as the non-
canonical kinases TBK1 and inhibitor of κB kinase ε (IKKε,
encoded by IKBKE) all seem to contribute to RIPK1 inactivation
through phosphorylation in order to prevent cell death (Dondelinger
et al., 2017, 2015; Jaco et al., 2017; Lafont et al., 2018;Menon et al.,
2017; Xu et al., 2018). Intriguingly, they cannot substitute for each
other; if only one of these three distinct cell death checkpoints fails
to operate properly, the other two checkpoints are not sufficient to
prevent the RIPK1 transition to complex II (Lafont et al., 2018).
Interestingly, it has been shown for TBK1 and IKKε that their
recruitment largely depends onM1 ubiquitin linkages, and that their
activation at complex I is mediated by NEMO; this partly explains
the pro-survival property of LUBAC (Lafont et al., 2018). After
dissociation from complex I, RIPK1 recruits the Fas-associated
death domain protein (FADD), caspase-8, cellular FLICE-like
inhibitory protein (cFLIP, also known as CFLAR), RIPK3 and
mixed lineage kinase domain-like protein (MLKL) (Feoktistova
et al., 2011; He et al., 2009; Oberst et al., 2011; Sun et al., 2012;
Vanlangenakker et al., 2011). Complex II can induce cell death
through two distinct processes: apoptosis or programmed necrosis,
also known as necroptosis (Annibaldi andMeier, 2018) (see poster).
The cell death mode that TNF induces depends on expression and
activity of the various components that are involved in these
processes. In summary, LUBAC and its activity are crucial for
maintaining the balance between the gene-activatory and cell death-
inducing outputs of TNF signalling through stabilisation of complex
I and prevention of complex II formation.
Linear ubiquitin-cleaving deubiquitinases
To date, two DUBs have been shown to be capable of cleaving M1-
linked ubiquitin, OTULIN and CYLD (Keusekotten et al., 2013;
Rivkin et al., 2013; Sato et al., 2015) (see poster). Both form
complexes with LUBAC and are crucial for the regulation of TNFR1
signalling output (Draber et al., 2015; Kupka et al., 2016a; Schaeffer
et al., 2014; Takiuchi et al., 2014). A third DUB, A20, is another
major regulator of TNFR1 signalling, although it now appears that the
majority of its effect in this pathway is independent of its DUB
activity, but rather depends on its ability to stabilise linear ubiquitin
chains (Draber et al., 2015; Tokunaga et al., 2012; Verhelst et al.,
2012; Yamaguchi and Yamaguchi, 2015) (see Box 1).
OTULIN
OTULIN is the only known DUB that exclusively cleaves linear
ubiquitin chains (Keusekotten et al., 2013; Rivkin et al., 2013). The
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exquisite specificity of OTULIN for linear ubiquitin can be attributed
to two features: (1) its high affinity to M1-linked di-ubiquitin, which
is more than 100-fold higher than to the structurally similar, albeit
distinct, K63-linked di-ubiquitin; (2) a process called ‘substrate-
assisted catalysis’, which improves the interaction between linear
chains and the catalytic domain of OTULIN (Keusekotten et al.,
2013). OTULIN is located in the cytosol and even though it
constitutively interacts with HOIP through its PUB-interacting
motif (PIM), it does not form part of the TNFR1-SC (Draber et al.,
2015; Elliott et al., 2014; Schaeffer et al., 2014; Takiuchi et al.,
2014). It was suggested that it exerts its function exclusively in the
cytosol by counteracting LUBAC auto-ubiquitination (see poster).
This appears to be a prerequisite for proper recruitment of LUBAC
to TNFR1 and other receptor complexes, and subsequent adequate
signalling output (Draber et al., 2015; Heger et al., 2018). The tight
regulation of linear ubiquitin chains on LUBAC is crucial for proper
signalling, as cells that harbour inactive OTULIN not only display
increased levels of linear ubiquitination but are also sensitised to
TNF-induced cell death (Draber et al., 2015; Heger et al., 2018).
This is due to decreased formation of complex I, which in turn
results in enhanced formation of the death-inducing complex II.
Cells that are deficient for LUBAC components present highly
similar phenotypes to those with inactive OTULIN, which suggests
that the main role of OTULIN is to promote LUBAC function by
suppressing its auto-ubiquitination, thereby enhancing LUBAC
activity, rather than counteracting it (Draber et al., 2015; Heger
et al., 2018; Peltzer et al., 2018, 2014).
CYLD
CYLD holds a crucial role in TNF signalling by regulating both
gene-activatory signalling (Brummelkamp et al., 2003; Kovalenko
et al., 2003; Reiley et al., 2004) and cell death-inducing signalling
(Hitomi et al., 2008). The ubiquitin-specific proteases (USP)
domain of CYLD dictates specificity for cleavage of M1 and K63
linkages (Komander et al., 2009; Ritorto et al., 2014; Sato et al.,
2015). CYLD interacts with HOIP indirectly through SPATA2
(Elliott et al., 2016; Kupka et al., 2016a; Schlicher et al., 2016;
Wagner et al., 2016). Following TNF stimulation, SPATA2 is
required for CYLD recruitment to the TNFR1-SC (see poster);
there, CYLD hydrolyses M1 and K63 linkages in ubiquitin chains
on various substrates, including TNFR1, TRADD, RIPK1 and
NEMO, which moderates TNF-induced gene activation (Draber
et al., 2015; Elliott et al., 2016; Kovalenko et al., 2003; Kupka et al.,
2016a). Absence of CYLD or SPATA2 renders cells resistant to
TNF-induced apoptosis and necroptosis. This is due to stabilisation
of complex I, leading to enhanced gene activation and subsequent
production of pro-survival factors (Lork et al., 2017).
In summary, both linear ubiquitin-specific DUBs serve key roles
in regulating the TNFR1 signalling output by fine-tuning levels of
M1-linked ubiquitin, both at the receptor complex and in the
cytosol.
Linear ubiquitin in disease
The crucial physiological roles of LUBAC and linear ubiquitin are
illustrated by the discoveries of various human diseases that result
from deregulated M1-linked ubiquitination. A recently identified
patient with a homozygous missense mutation in the HOIP-
encoding RNF31 gene showed multi-organ auto-inflammation,
recurrent viral and bacterial infections and other symptoms
(Boisson et al., 2015). The missense mutation in RNF31 results in
reduction of HOIP mRNA levels by half and barely detectable
HOIP protein levels in patient-derived cells (Boisson et al., 2015).
These clinical and cellular phenotypes largely overlap with
phenotypes that are observed in several – but intriguingly not
all – individuals with mutations in the HOIL-1-encoding RBCK1
gene (see poster). One report described three patients with loss-of-
expression and loss-of-function mutations in RBCK1
(Boisson et al., 2012). These patients displayed a syndrome
encompassing auto-inflammation, immunodeficiency and
muscular amylopectinosis, which resulted in their premature death
during infancy. Similar to what was seen with HOIP mutations,
these mutations result in decreased expression of HOIL-1 and lower
expression of the other LUBAC components (Boisson et al., 2012).
The observed auto-inflammatory phenotype in both HOIP- and
HOIL-1-deficient patients presumably results from elevated levels
of necroptosis – the pro-inflammatory-regulated type of cell death
(Vanden Berghe et al., 2014; Weinlich et al., 2017) – upon LUBAC
deficiency.
Interestingly, not all truncating mutations in RBCK1 lead to severe
immune pathology, as they can also cause glycogen storage disease
and, in some cases, a phenotype that consists of muscle weakness,
progressive cardiomyopathy and signs of amylopectinosis, yet
without immunodeficiency or hyper-inflammation (Nilsson et al.,
2013; Wang et al., 2013). The pathological divergence of HOIL-1-
deficient patients could be explained by different mutation sites in
RBCK1, as most of the non-immune disease patients harbour
homozygous mutations in the central or C-terminal part of HOIL-1,
whereas immune disease patients have mutations affecting the
N-terminus of HOIL-1 so that most functional domains are lacking.
Additionally, two rare germline RNF31 single-nucleotide
Box 1. The DUB A20 regulates linear ubiquitin during
TNFR1 signalling
A20 contains a deubiquitinating OTU domain at the N-terminus and
seven zinc-finger domains in its C-terminus. The specificity of DUB
activity of A20 and its relevance for A20 activity in TNF signalling is highly
controversial. Initially, A20 was thought to serve as an NF-κB suppressor
by cleaving K63-linked ubiquitin and additionally to act as an E3 ligase
(Wertz et al., 2004). Subsequent studies, however, showed A20
specificity towards K11- and K48-linked ubiquitin (Evans et al., 2004;
Komander and Barford, 2008; Lin et al., 2008; Mevissen et al., 2013;
Ritorto et al., 2014) and suggested an indirect ubiquitin ligase activity for
A20 when complexed with other E3s (Shembade et al., 2008, 2009).
Several models explaining the repressive role of A20 in TNF-induced
gene activation have been put forward, including targeting RIPK1 for
proteasomal degradation (Wertz et al., 2004) and through
deubiquitinating multiple TNFR1-SC components (Lork et al., 2017).
However, emerging evidence shows that the regulatory role of A20 in
TNF-induced gene activation depends on its non-catalytic functions.
Zinc finger 7 of A20 binds M1-linked ubiquitin (Tokunaga et al., 2012;
Verhelst et al., 2012), which is required for A20 recruitment to the
TNFR1-SC (Draber et al., 2015). In doing so, A20 does not only protect
M1-ubiquitin linkages from cleavage by CYLD, but also competes with
other M1-ubiquitin-binding proteins, including NEMO, thereby negatively
regulating NF-κB signalling (Bosanac et al., 2010; Draber et al., 2015;
Verhelst et al., 2012). The non-catalytic functions of A20 in TNF
signalling have been confirmed in vivo (De et al., 2014; Lu et al., 2013;
Verhelst et al., 2014).
Additionally, A20 has been attributed a negative role in TNF-induced
cell death (see poster). A20 zinc finger 7 mutant cells fail to prevent TNF-
induced death, most likely because A20 can no longer bind to M1-
ubiquitin chains on components of the TNFR1-SC. This would have
protected these components from CYLD-mediated hydrolysis and,
consequently, the release of RIPK1 and the formation of complex II
(Draber et al., 2015; Yamaguchi and Yamaguchi, 2015). Furthermore,
A20 has been shown to restrict ubiquitination of RIPK3 and its binding to
RIPK1, thereby protecting cells from necroptosis (Onizawa et al., 2015).
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polymorphisms (SNPs) have been shown to be specifically enriched
in patients with activated B-cell-like subtype of diffuse large B-cell
lymphoma (ABC-DLBCL) compared to what is found in healthy
individuals (Yang et al., 2014). These SNPs result in two recurrent
missense mutations in HOIP, both affecting the UBA domain of
HOIP. At a functional level, these missense mutations have been
suggested to increase the association of HOIP with HOIL-1, which
could augment the activity of LUBAC and, consequently, of NF-κB
(Yang et al., 2014).
Furthermore, homozygous mutations in the OTULIN gene have
been reported in autoimmune disease patients (Damgaard et al.,
2016; Zhou et al., 2016), which led to neonatal-onset fever, skin
rashes, auto-antibody production, diarrhoea, arthritis and failure to
thrive. These pathologies were named OTULIN-related auto-
inflammatory syndrome (ORAS) (Damgaard et al., 2016) and
otulipenia (Zhou et al., 2016). At the molecular level, some
mutations are located near the ubiquitin-binding sites of OTULIN
and abolish its catalytic activity (Damgaard et al., 2016). In
addition, a frameshift mutation that introduces a premature stop
codon results in undetectable OTULIN expression in patient-
derived fibroblasts (Zhou et al., 2016). As described above, it has
now been clarified that OTULIN, rather than negatively regulating
LUBAC activity, is required for it, and deficiency in LUBAC and
OTULIN causes similar phenotypes and subsequent embryonic
lethality in mice (Draber et al., 2015; Heger et al., 2018; Peltzer
et al., 2018, 2014). In line with this, patients with OTULIN
deficiencies show pathologies that closely resemble those from
patients with HOIL-1 or HOIP mutations. Thus, the disease
aetiology of OTULIN-deficient patients is presumably very
similar to that of LUBAC-deficient patients.
In summary, the identification of patients with mutations in genes
encoding LUBAC components or/and OTULIN illustrates the
critical importance of the appropriate physiologically intended level
of linear ubiquitination for tissue homeostasis.
Conclusions and perspectives
It is now widely recognised that linear ubiquitination is a crucial
regulator of the majority of immune signalling pathways and the list
of pathways that employ LUBAC-driven ubiquitination in their
signalling is growing (see Box 2). Studies on LUBAC and M1-
linked ubiquitin have revealed its importance at the functional level
in cellular systems, and at the physiological and pathological level
by studying LUBAC components, and the lack thereof in vivo in
mice and men. However, despite the considerable gain in
knowledge over the past decade, we are far from a comprehensive
understanding of the role of LUBAC in cell signalling. It now
appears that we have merely broken sweat on what has turned out to
be a marathon rather than a sprint: the intent to crack the (linear)
ubiquitin code of immune signalling.
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